Research advances in sorafenib:a multiple targeted anti-tumor agent / 中国药理学通报
Chinese Pharmacological Bulletin
;
(12)2003.
Article
in Chinese
| WPRIM
| ID: wpr-564081
ABSTRACT
Sorafenib,a novel oral multikinase inhibitor,targts on serine/threonine kinase and tyrosine kinases receptor of the tumor cells and vasculature.So Sorafenib can inhibit the tumor cell proliferation and revascularization.400 mg sorafenib administered twice a day is chosen as the recommended dosage for several phase Ⅰ studies,and it shows broad-spectrum antitumor activity in renal cancer,hepatocellular carcinoma,melanoma and non-small-cell lung cancer(NSCLC)in phase Ⅱ and Ⅲ clinical trials.Now FDA has approved the usage of sorafenib in renal cancer therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Pharmacological Bulletin
Year:
2003
Type:
Article
Similar
MEDLINE
...
LILACS
LIS